|
|
|
|
 |
|
|
PORTFOLIO
Proterec
www.proterec.com
An R&D company, in the field of bio-catalysis, which provides solutions to the chemical synthesis industry through the use of its novel proprietary technology of In Vitro Protein Recombination (IVPR).
Genova Ltd.
www.genovael.com
A company that has developed proprietary technology for small scale production of natural gas from bio-mass waste. The generated gas will fuel a gas turbine and produce electricity. The product was initially developed to treat olive-oil production waste that poses an environmental problem. Further R&D is showing that its units will be able to also deal with most oil waste (cake), sugar bagasse, wine production waste, tomato and orange peels etc.
The company is developing compact power-generation units with capacity ranging from 200-500 KWh. Such units will be able to supply local production plants and villages even if not connected to the grid.
Medidermis Ltd.
AcVx-25 is a novel TOPICAL therapeutic for the treatment of Acne Vulgaris, presently in phase IIb clinicals. PI/IIa (n=12) and PIIb (n=30) studies have demonstrated a high safety, ease of use, faster onset of effect and greater reduction in clinical acne score than market-leading topical Differin (adalapene). The active agent has a well-known safety profile with very low toxicity. The newly identified mechanism of action constitutes a unique approach to acne therapy. It is a low cost topical, highly stable, and easy to manufacture.
The development plan includes a rapid clinical development and completion of IND and phase II within 22-24 mo. including regulatory approvals.
Efficacy/comparative studies (vs. treinoin) to date have shown a high efficacy beyond any topical competitor performance and a low incidence of side effects.
Endo-Rythm
Endo-Rhythm is developing novel Active Diet Management system based on body biological rhythm synchronization concept. The new system is oriented for professional and consumers market enabling more effective diet and wellness management. The company has developed a prototype that is undergoing clinical validation. The new product is expected to be launched in 2008.
The company was founded in 2007 with a Seed investment by NRVision ventures.
Simplima
www.simplima.com
A software company that has developed technology that enables secure lending, distribution, ownership, management and use of digital assets. With Simplima's technology, an owner of digital content can control its access and protect valuable digital assets (documents, audio, game and video) from unauthorized use and distribution.
Simplima has developed and patented technology that prevents automatic hacks, thus impairing hackers', and other unauthorized persons' ability to cause damage (e.g. financial, privacy and copy right violation) to organizations producing and distributing digital assets.
This technology is superior to the DNA shuffling technology which requires that proteins share significant amounts of DNA. The technology will be instrumental in reducing the cost of production of bio-diesel, second generation cellulitic ethanol, and for shortening and cutting the cost of manufacture of pharmaceuticals.
|
|
|
|
